Osteonecrosis of the Jaw and Fosamax
Generically known as alendronate sodium, Fosamax
is a popular drug that belongs to the group of
biphosphonates and is known as a treatment for
osteoporosis and other diseases related to bone
mineral density problems. As of now, osteonecrosis
of the jaw (ONJ) has been found out to be its serious
side effect causing the drugs to face serious
problems. Currently, this has made a New York
dentist to addressed questions about Fosamax and
dental health in a leading newspaper.
Osteonecrosis of the jaw is a severe bone disease that
affects the jaws, both the maxilla and the mandible.
When the blood supply to a certain bone tissue is reduced (ischemia), damage and death to the
areas of jaw bone occurs. By and large, it the dentists who first detect ONJ after a dental surgical
procedure such as tooth extraction.
As previously told to the public, the cases of osteonecrosis of the jaw caused by Fosamax and
other biphosphonates are relatively rare and negligible. But a study brought out on the Journal of
the American Dental Association shows a considerable 4% of patients taking even the oral form
of Fosamax are likely to develop osteonecrosis of the jaw.
Although it may occur asymptomatically, among the early signs of ONJ are loose teeth and
exposed bone. There may also be pain on the jaw or gum as well as swelling or infection and
dramatic gum loss. The most distinctive sign of ONJ however is the disclosure of mandibular
and/or maxillary bone through a sore in the gums that is not convalescing.
The regimen for ONJ would depend on the etiology or the cause of the disease and the severity
of the disease process. Nonsurgical management of the biphosphonate-related ONJ may consist
of antimicrobial rinses, systemic antibiotics, systemic or topical antifungals, discontinuation of
the biphosphonate therapy and avoiding invasive dental therapy.
Sadly surgical treatments for patients with ONJ related to biphosphonates like Fosamax produce
poor results because of the compromised ability of the bone to recuperate. Sagacious
debridement, pain medication and other nonsurgical methods are more preferred means to treat
this type of ONJ rather than the more intrusive surgical interventions. It is essential to diagnose
and treat ONJ at an early stage to let alone the irreversible bone collapse that may result in the
facial deformity of the patient.
Despite how disturbing it is, the decision of withdrawing from your Fosamax therapy needs to be
brought up with your doctor first. Furthermore, Fosamax femur fractures are also known to be
a side effect of this drug.